Immunotherapy plus chemo before surgery for cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- You have not received any prior cancer treatment for cervical cancer (like chemo, radiation, or immunotherapy).
- You are willing and able to have surgery to remove the uterus (called a radical hysterectomy).
- You have good kidney, liver, and blood cell function, and are not pregnant (if female).
- You do not have other active cancers, serious infections, or autoimmune diseases needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if the treatment shrinks the tumor enough to make surgery more effective.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This study tests a combination of two immunotherapy drugs and a targeted antibody-drug before standard treatment for locally advanced cervical cancer. The goal is to see if this triple therapy can shrink tumors more effectively before surgery or radiation.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.